ERBB2 and breast carcinoma: Moreover, the low-risk patients with HR-positive and HER2-negative breast cancer who were stratified by a 21-gene assay were also recommended to use endocrine therapy alone, with no need for adjuvant chemotherapy (27), supporting our results that low-risk patients stratified by RecurIndex assay could omit adjuvant chemotherapy to avoid overtreatment.